Tarsus Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
TARS$73.83+4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consol idated Balance Sheets
(In thousands, except share and par value amounts)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| (unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $136,530 | $183,641 |
| Restricted cash | — | 560 |
| Marketable securities | 173,082 | 233,627 |
| Accounts receivable, net | 100,436 | 85,057 |
| Inventory | 5,159 | 4,372 |
| Other receivables | 1,670 | 2,052 |
| Prepaid expenses | 28,541 | 13,473 |
| Total current assets | 445,418 | 522,782 |
| Restricted cash, non-current | 2,382 | 2,002 |
| Inventory, non-current | 2,525 | 2,532 |
| Property and equipment, net | 20,719 | 11,665 |
| Intangible assets, net | 16,645 | 7,366 |
| Operating lease right-of-use assets | 10,393 | 10,080 |
| Long-term investments | 6,682 | 3,870 |
| Other assets | 735 | 1,861 |
| Total assets | $505,499 | $562,158 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $34,694 | $16,387 |
| Accrued payroll and benefits | 34,335 | 17,779 |
| Other accrued liabilities | 158,085 | 101,529 |
| Total current liabilities | 227,114 | 135,695 |
| Long-term debt, net | 72,935 | 72,438 |
| Contingent consideration, non-current | 85,689 | — |
| Other long-term liabilities | 15,732 | 10,599 |
| Total liabilities | 401,470 | 218,732 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 49,303,413 shares issued and outstanding at September 30, 2026 (unaudited); 42,553,931 shares issued and outstanding at December 31, 2025 | 7 | 6 |
| Additional paid-in capital | 1,225,416 | 769,667 |
| Accumulated other comprehensive income (loss) | (914) | 381 |
| Accumulated deficit | (1,120,480) | (426,628) |
| Total stockholders’ equity | 104,029 | 343,426 |
| Total liabilities and stockholders’ equity | $505,499 | $562,158 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.